GLP1R and Parkinson disease: The resulting pro-inflammatory cytokines released by activated microglia contribute to dopaminergic neuronal injury, accelerating the neurodegenerative processes characteristic of Parkinson’s disease (PD), pointing to the rationale for antidiabetic drugs—particularly GLP-1 receptor agonists and PPAR-γ as promising therapeutic options in PD (Zhang et al. 2024).